NCT06964165 2025-11-26
A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)
Tesaro, Inc.
Phase 2 Terminated
Clinical Trials
11 trialsNCT05169437 2025-10-29
PAVO
Tempus AI
Phase 2 Terminated
NCT04159155 2025-08-12
CAN-STAMP
University Health Network, Toronto
Phase 2/3 Terminated
NCT05523440 2025-03-28
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
University of Oklahoma
Phase 2 Terminated
NCT03891576 2025-01-17
Newton
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
NCT04826198 2024-12-05
REVOCAN
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Terminated
NCT03644342 2024-09-03
NIVIX
Baylor College of Medicine
Phase 1/2 Terminated
NCT04267939 2023-12-21
ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
Bayer
Phase 1 Terminated
NCT03944902 2023-11-21
BRCA
University of Alabama at Birmingham
Phase 1 Terminated
NCT01905592 2022-11-15
BRAVO
Tesaro, Inc.
Phase 3 Terminated
NCT01227941 2016-10-19
MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)
Tesaro, Inc.
Phase 1 Terminated